Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

Erin R. Gardner, Herman Burger, Ron H. van Schaik, Allan T. van Oosterom, Ernst A. de Bruijn, Gunther Guetens, Hans Prenen, Floris A. de Jong, Sharyn D. Baker, Susan E. Bates, William D. Figg, Jaap Verweij, Alex Sparreboom*, Kees Nooter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

132 Scopus citations


Objective: Our objective was to explore the relationships between imatinib pharmacokinetics and 9 allelic variants in 7 genes coding for adenosine triphosphate-binding cassette transporters (ABCB1 and ABCG2) and enzymes (cytochrome P450 [CYP] 2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) of putative relevance for imatinib. Methods: Imatinib transport in vitro was studied by use of human embryonic kidney 293 cells transfected with wild-type ABCG2 and an ABCG2 Q141K clone. Steady-state pharmacokinetics of imatinib was obtained in 82 patients with gastrointestinal stromal tumors treated with oral imatinib at doses ranging from 100 to 1000 mg/d. Genotyping was carried out via direct sequencing or restriction fragment length polymorphism-based techniques. Results: Human embryonic kidney 293 cells transfected with ABCG2 Q141K exhibited greater drug accumulation in vitro in comparison with cells expressing wild-type ABCG2 (P = .028). However, pharmacokinetic parameters of imatinib in vivo were not statistically significantly different in 16 patients who were heterozygous for ABCG2 421C>A compared with 66 patients carrying the wild-type sequence (P = .479). The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695). Pharmacokinetic parameters were not related to any of the other multiple-variant genotypes (P ≥ .230), possibly because of the low allele frequencies. Conclusions: This study indicates that common genetic variants in the evaluated genes have only a limited impact on the pharmacokinetics of imatinib. Further investigation is required to quantitatively assess the clinical significance of homozygous variant ABCG2 and CYP2D6 genotypes in patients treated with imatinib.

Original languageEnglish
Pages (from-to)192-201
Number of pages10
JournalClinical Pharmacology and Therapeutics
Issue number2
StatePublished - Aug 2006
Externally publishedYes


Dive into the research topics of 'Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib'. Together they form a unique fingerprint.

Cite this